{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T10:52:35Z","timestamp":1778064755954,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neurotrophic keratopathy (NK) is an orphan disease, with an estimated prevalence of 1\u20135\/10,000. No data regarding the incidence exists. The primary aim was to evaluate incidence and prevalence of NK at a tertiary referral center in Germany, and the secondary aim was to analyze demographic parameters, etiology, and clinical features and therapeutic outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and material<\/jats:title>\n                <jats:p>All patients treated for NK with serum eye drops (SED), amnionic membrane transplantation (AMT), or penetrating keratoplasty (PK) in 2013\u20132017 were identified. Age, sex, etiology of NK, visual acuity, disease stage, treatment, and visual acuity were analyzed. Incidence and prevalence of NK in our hospital and the overall population of the city were calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In 63 eyes of 60 patients (56.7% male; 68\u2009\u00b1\u200916\u00a0years), the most common underlying diseases were herpetic infections (23.8%), neurological causes (19%), and diabetes mellitus (14.3%). The annual incidence of NK in our tertiary referral center ranges between 5\/10,000 and 3\/10,000, the prevalence between 9\/10,00 and 22\/10,000. In all patients treated with corneal ulcers, the prevalence was up to 27% (2706\/10,000). The incidence in the overall population is estimated at 0.1\u20130.3\/10,000, the prevalence at 0.2\u20130.5\/10,000 to 0.5\/10,000.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Based on our assessment, the prevalence of NK in the overall population is lower than estimated before. However, in patients with corneal ulcers, the percentage of NK is comparably high. The disease may still be underdiagnosed due to the variety of underlying disorders and unknown comorbidities. Thus, in cases of therapy-refractive superficial keratopathy or ulcerations, NK should be considered more frequently.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-021-05535-z","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T08:02:42Z","timestamp":1641456162000},"page":"1961-1973","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Incidence, prevalence, and outcome of moderate to severe neurotrophic keratopathy in a German tertiary referral center from 2013 to 2017"],"prefix":"10.1007","volume":"260","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-1289","authenticated-orcid":false,"given":"Mathias","family":"Roth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Dierse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Alder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Holtmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Geerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"5535_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00347-004-1140-z","volume":"102","author":"C Cursiefen","year":"2005","unstructured":"Cursiefen C, Seitz B, Kruse FE (2005) Neurotrophe Keratopathie Der Ophthalmol 102:7\u201314. https:\/\/doi.org\/10.1007\/s00347-004-1140-z","journal-title":"Neurotrophe Keratopathie Der Ophthalmol"},{"key":"5535_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00347-019-0946-7","volume":"116","author":"S Mergler","year":"2019","unstructured":"Mergler S, Dietrich-Ntoukas T, Pleyer U (2019) Neurotrophic keratopathy: principles, diagnostics and treatment. Ophthalmologe 116:797\u2013810. https:\/\/doi.org\/10.1007\/s00347-019-0946-7","journal-title":"Ophthalmologe"},{"key":"5535_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2018.04.003","volume":"66","author":"HS Dua","year":"2018","unstructured":"Dua HS, Said DG, Messmer EM et al (2018) Neurotrophic keratopathy. Prog Retin Eye Res 66:107\u2013131. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.04.003","journal-title":"Prog Retin Eye Res"},{"key":"5535_CR4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2147\/OPTH.S45921","volume":"8","author":"A Lambiase","year":"2014","unstructured":"Lambiase A, Sacchetti M (2014) Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol 8:571. https:\/\/doi.org\/10.2147\/OPTH.S45921","journal-title":"Clin Ophthalmol"},{"key":"5535_CR5","unstructured":"www.orpha.net: ORPHA:137596. https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=EN&Expert=137596 (Last accessed: 22.11.2021)"},{"key":"5535_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00347-019-0946-7","volume":"116","author":"S Mergler","year":"2019","unstructured":"Mergler S, Dietrich-Ntoukas T, Pleyer U (2019) Neurotrophe Keratopathie Der Ophthalmol 116:797\u2013810. https:\/\/doi.org\/10.1007\/s00347-019-0946-7","journal-title":"Neurotrophe Keratopathie Der Ophthalmol"},{"key":"5535_CR7","doi-asserted-by":"publisher","unstructured":"Alder J, Mertsch S, Menzel-Severing J, Geerling G (2019) Aktuelle und experimentelle Therapieans\u00e4tze bei neurotropher Keratopathie [Current and experimental treatment approaches for neurotrophic keratopathy]. Der Ophthalmol 1\u201310.https:\/\/doi.org\/10.1007\/s00347-018-0843-5","DOI":"10.1007\/s00347-018-0843-5"},{"key":"5535_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00417-006-0257-y","volume":"244","author":"S Schrader","year":"2006","unstructured":"Schrader S, Wedel T, Moll R, Geerling G (2006) Combination of serum eye drops with hydrogel bandage contact lenses in the treatment of persistent epithelial defects. Graefe\u2019s Arch Clin Exp Ophthalmol 244:1345\u20131349. https:\/\/doi.org\/10.1007\/s00417-006-0257-y","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"5535_CR9","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/bjo.85.10.1188","volume":"85","author":"AC Poon","year":"2001","unstructured":"Poon AC, Geerling G, Dart JKG et al (2001) Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol 85:1188\u20131197. https:\/\/doi.org\/10.1136\/bjo.85.10.1188","journal-title":"Br J Ophthalmol"},{"key":"5535_CR10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1136\/bjo.2004.044347","volume":"88","author":"G Geerling","year":"2004","unstructured":"Geerling G, MacLennan S, Hartwig D (2004) Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol 88:1467\u20131474. https:\/\/doi.org\/10.1136\/bjo.2004.044347","journal-title":"Br J Ophthalmol"},{"key":"5535_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jtos.2019.11.008","volume":"18","author":"S Saad","year":"2020","unstructured":"Saad S, Abdelmassih Y, Saad R et al (2020) Neurotrophic keratitis: frequency, etiologies, clinical management and outcomes. Ocul Surf 18:231\u2013236. https:\/\/doi.org\/10.1016\/j.jtos.2019.11.008","journal-title":"Ocul Surf"},{"key":"5535_CR12","doi-asserted-by":"publisher","unstructured":"Munguia N, Mozayeni BR, Wright TF, Herbst KL (2021) Dercum\u2019s disease: estimating the prevalence of a rare painful loose connective tissue disease. Futur Rare Dis 1:FRD4. https:\/\/doi.org\/10.2217\/frd-2020-0004","DOI":"10.2217\/frd-2020-0004"},{"key":"5535_CR13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.ophtha.2004.11.052","volume":"112","author":"M Labetoulle","year":"2005","unstructured":"Labetoulle M, Auquier P, Conrad H et al (2005) Incidence of herpes simplex virus keratitis in France. Ophthalmology 112:888\u2013895. https:\/\/doi.org\/10.1016\/j.ophtha.2004.11.052","journal-title":"Ophthalmology"},{"key":"5535_CR14","unstructured":"BfArM Forschungsdatenzentrum. https:\/\/www.bfarm.de\/DE\/Das-BfArM\/Aufgaben\/Forschungsdatenzentrum\/_node.html (Last accessed: 22.11.2021)"},{"key":"5535_CR15","doi-asserted-by":"publisher","unstructured":"Murray LT, McCormack J, Grobeiu I, et al (2020) Development of the neurotrophic keratopathy questionnaire: qualitative research. J Patient-Reported Outcomes 4.https:\/\/doi.org\/10.1186\/s41687-020-00192-y","DOI":"10.1186\/s41687-020-00192-y"},{"key":"5535_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/J.OPHTHA.2003.10.019","volume":"111","author":"Y Matsumoto","year":"2004","unstructured":"Matsumoto Y, Dogru M, Goto E et al (2004) Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology 111:1115\u20131120. https:\/\/doi.org\/10.1016\/J.OPHTHA.2003.10.019","journal-title":"Ophthalmology"},{"key":"5535_CR17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/ICL.0000000000000133","volume":"41","author":"HY Hsu","year":"2015","unstructured":"Hsu HY, Modi D (2015) Etiologies, quantitative hypoesthesia, and clinical outcomes of neurotrophic keratopathy. Eye Contact Lens 41:314\u2013317. https:\/\/doi.org\/10.1097\/ICL.0000000000000133","journal-title":"Eye Contact Lens"},{"key":"5535_CR18","doi-asserted-by":"publisher","unstructured":"Pflugfelder SC, Massaro-Giordano M, Perez VL, et al (2020) Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial. In: Ophthalmology. Elsevier Inc., pp 14\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2019.08.020","DOI":"10.1016\/j.ophtha.2019.08.020"},{"key":"5535_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/bjo.84.8.826","volume":"84","author":"H Chen","year":"2000","unstructured":"Chen H, Pires R, Tseng S (2000) Amniotic membrane transplantation for severe neurotrophic corneal ulcers. Br J Ophthalmol 84:826\u2013833. https:\/\/doi.org\/10.1136\/bjo.84.8.826","journal-title":"Br J Ophthalmol"},{"key":"5535_CR20","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","volume":"125","author":"S Bonini","year":"2018","unstructured":"Bonini S, Lambiase A, Rama P et al (2018) Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology 125:1332\u20131343. https:\/\/doi.org\/10.1016\/j.ophtha.2018.02.022","journal-title":"Ophthalmology"},{"key":"5535_CR21","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.ophtha.2018.03.004","volume":"125","author":"P Rama","year":"2018","unstructured":"Rama P, Sainz de la Maza M, Chao W et al (2018) Phase I trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology 125:1468\u20131471. https:\/\/doi.org\/10.1016\/j.ophtha.2018.03.004","journal-title":"Ophthalmology"},{"key":"5535_CR22","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1097\/ICO.0000000000000587","volume":"34","author":"R Yanai","year":"2015","unstructured":"Yanai R, Nishida T, Chikama TI et al (2015) Potential new modes of treatment of neurotrophic keratopathy. Cornea 34:S121\u2013S127. https:\/\/doi.org\/10.1097\/ICO.0000000000000587","journal-title":"Cornea"},{"key":"5535_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/ICO.0000000000000348","volume":"34","author":"YC Lee","year":"2015","unstructured":"Lee YC, Kim SY (2015) Treatment of neurotrophic keratopathy with nicergoline. Cornea 34:303\u2013307. https:\/\/doi.org\/10.1097\/ICO.0000000000000348","journal-title":"Cornea"},{"key":"5535_CR24","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0161-6420(00)00163-9","volume":"107","author":"S Bonini","year":"2000","unstructured":"Bonini S, Lambiase A, Rama P et al (2000) Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology 107:1347\u20131351. https:\/\/doi.org\/10.1016\/S0161-6420(00)00163-9","journal-title":"Ophthalmology"},{"key":"5535_CR25","doi-asserted-by":"publisher","unstructured":"Yoon KC, You IC, Im SK, et al (2007) Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis. Ophthalmology 114.https:\/\/doi.org\/10.1016\/j.ophtha.2006.12.014","DOI":"10.1016\/j.ophtha.2006.12.014"},{"key":"5535_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/08820538.2013.768678","volume":"29","author":"E Turkoglu","year":"2014","unstructured":"Turkoglu E, Celik E, Alagoz G (2014) A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis. Semin Ophthalmol 29:119\u2013126. https:\/\/doi.org\/10.3109\/08820538.2013.768678","journal-title":"Semin Ophthalmol"},{"key":"5535_CR27","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0014-4835(03)00050-2","volume":"76","author":"LJ M\u00fcller","year":"2003","unstructured":"M\u00fcller LJ, Marfurt CF, Kruse F, Tervo TMT (2003) Corneal nerves: structure, contents and function. Exp Eye Res 76:521\u2013542. https:\/\/doi.org\/10.1016\/S0014-4835(03)00050-2","journal-title":"Exp Eye Res"},{"key":"5535_CR28","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s10792-017-0582-7","volume":"38","author":"RM Sanchez-Avila","year":"2018","unstructured":"Sanchez-Avila RM, Merayo-Lloves J, Riestra AC et al (2018) Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops. Int Ophthalmol 38:1193\u20131204. https:\/\/doi.org\/10.1007\/s10792-017-0582-7","journal-title":"Int Ophthalmol"},{"key":"5535_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-64489-0","volume":"10","author":"YS Chang","year":"2020","unstructured":"Chang YS, Tai MC, Ho CH et al (2020) Risk of corneal ulcer in patients with diabetes mellitus: a retrospective large-scale cohort study. Sci Rep 10:1\u20136. https:\/\/doi.org\/10.1038\/s41598-020-64489-0","journal-title":"Sci Rep"},{"key":"5535_CR30","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/sj.eye.6702053","volume":"20","author":"A Lockwood","year":"2006","unstructured":"Lockwood A, Hope-Ross M, Chell P (2006) Neurotrophic keratopathy and diabetes mellitus Eye 20:837\u2013839. https:\/\/doi.org\/10.1038\/sj.eye.6702053","journal-title":"Neurotrophic keratopathy and diabetes mellitus Eye"},{"key":"5535_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00347-019-00980-y","volume":"117","author":"JN Lueke","year":"2020","unstructured":"Lueke JN, Holtmann C, Beseoglu K, Geerling G (2020) Corneal neurotization. Ophthalmologe 117:248\u2013252. https:\/\/doi.org\/10.1007\/s00347-019-00980-y","journal-title":"Ophthalmologe"},{"key":"5535_CR32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jtos.2019.09.002","volume":"17","author":"A Di Zazzo","year":"2019","unstructured":"Di Zazzo A, Coassin M, Varacalli G et al (2019) Neurotrophic keratopathy: pros and cons of current treatments. Ocul Surf 17:619\u2013623. https:\/\/doi.org\/10.1016\/j.jtos.2019.09.002","journal-title":"Ocul Surf"},{"key":"5535_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3238\/arztebl.2011.0243","volume":"108","author":"M Pauklin","year":"2018","unstructured":"Pauklin M, Steuhl K-P, Thomasen H et al (2018) Amniotic membrane transplantation in the human eye. Dtsch Aerzteblatt Online 108:243\u2013249. https:\/\/doi.org\/10.3238\/arztebl.2011.0243","journal-title":"Dtsch Aerzteblatt Online"},{"key":"5535_CR34","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00347-007-1661-3","volume":"104","author":"B Seitz","year":"2007","unstructured":"Seitz B (2007) Amnionmembrantransplantation. Der Ophthalmol 104:1075\u20131079. https:\/\/doi.org\/10.1007\/s00347-007-1661-3","journal-title":"Der Ophthalmol"},{"key":"5535_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/J.SURVOPHTHAL.2003.10.004","volume":"49","author":"HS Dua","year":"2004","unstructured":"Dua HS, Gomes JA, King AJ, Maharajan VS (2004) The amniotic membrane in ophthalmology. Surv Ophthalmol 49:51\u201377. https:\/\/doi.org\/10.1016\/J.SURVOPHTHAL.2003.10.004","journal-title":"Surv Ophthalmol"},{"key":"5535_CR36","doi-asserted-by":"publisher","unstructured":"R\u00f6ck T, Bartz-Schmidt KU, Landenberger J, et al (2018) Amniotic membrane transplantation in reconstructive and regenerative ophthalmology. Ann Transplant 23:160\u2013165. https:\/\/doi.org\/10.12659\/AOT.906856","DOI":"10.12659\/AOT.906856"},{"key":"5535_CR37","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/01.ico.0000153102.19776.80","volume":"24","author":"S Khokhar","year":"2005","unstructured":"Khokhar S, Natung T, Sony P et al (2005) Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial. Cornea 24:654\u2013660. https:\/\/doi.org\/10.1097\/01.ico.0000153102.19776.80","journal-title":"Cornea"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05535-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05535-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05535-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T10:05:40Z","timestamp":1651485940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05535-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5535"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05535-z","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"28 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Before initiation of the study, approval was obtained from the Ethics Committee of the Medical Faculty of Duesseldorf (file number 6069R). The study adhered to the tenets of the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Due to the study type (retrospective data analysis), consent for participation was deemed unnecessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"MR reports personal fees from Bayer and personal fees from Thea Pharma, outside the submitted work. SD received an award from Bausch\u2009+\u2009Lomb, during the conduct of the study. GG reports grants and personal fees from Santen, personal fees from Chiesi, grants and personal fees from Novartis, personal fees from Med1Ventures, personal fees from Alcon, personal fees from Domp\u00e9, personal fees from Sun Pharma, personal fees from Allergan, personal fees from Shire, personal fees from Taylor & Francis, personal fees from Tearlab Inc., personal fees from Thea Pharma, and personal fees from Visufarma, outside the submitted work. JA and CH have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}